Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | PALB2 |
| Variant | R37H |
| Impact List | missense |
| Protein Effect | unknown |
| Gene Variant Descriptions | PALB2 R37H lies within the DNA-binding, and BRCA1 and RAD51-interacting regions of the Palb2 protein (UniProt.org). R37H results in decreased Brca1 binding and recruitment to DNA damage sites (PMID: 31757951), reduced Rad51 foci formation and intensity (PMID: 31586400), impaired homology-directed DNA repair activity, and failure to rescue PARP inhibitor sensitivity in PALB2-null cells in culture (PMID: 28319063, PMID: 31586400, PMID: 31757951), but in other studies demonstrates Brca1 binding and recruitment to DNA damage sites similar to wild-type Palb2 (PMID: 28319063, PMID: 31586400), and homology-directed DNA repair similar to wild-type in a reporter assay (PMID: 33964450), and therefore, its effect on Palb2 protein function is unknown. |
| Associated Drug Resistance | |
| Category Variants Paths |
PALB2 mutant PALB2 R37H |
| Transcript | NM_024675.4 |
| gDNA | chr16:g.23637951C>T |
| cDNA | c.110G>A |
| Protein | p.R37H |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| NM_001407300.1 | chr16:g.23637951C>T | c.110G>A | p.R37H | RefSeq | GRCh38/hg38 |
| NM_024675.3 | chr16:g.23637951C>T | c.110G>A | p.R37H | RefSeq | GRCh38/hg38 |
| NM_001407298.1 | chr16:g.23637951C>T | c.110G>A | p.R37H | RefSeq | GRCh38/hg38 |
| XM_017023672.2 | chr16:g.23637951C>T | c.110G>A | p.R37H | RefSeq | GRCh38/hg38 |
| NM_024675.4 | chr16:g.23637951C>T | c.110G>A | p.R37H | RefSeq | GRCh38/hg38 |
| NM_001407302.1 | chr16:g.23637951C>T | c.110G>A | p.R37H | RefSeq | GRCh38/hg38 |
| NM_024675 | chr16:g.23637951C>T | c.110G>A | p.R37H | RefSeq | GRCh38/hg38 |
| NM_001407297.1 | chr16:g.23637951C>T | c.110G>A | p.R37H | RefSeq | GRCh38/hg38 |
| NM_001407301.1 | chr16:g.23637951C>T | c.110G>A | p.R37H | RefSeq | GRCh38/hg38 |
| XM_017023672 | chr16:g.23637951C>T | c.110G>A | p.R37H | RefSeq | GRCh38/hg38 |
| XM_017023673.2 | chr16:g.23637951C>T | c.110G>A | p.R37H | RefSeq | GRCh38/hg38 |
| NM_001407299.1 | chr16:g.23637951C>T | c.110G>A | p.R37H | RefSeq | GRCh38/hg38 |
| XM_017023673 | chr16:g.23637951C>T | c.110G>A | p.R37H | RefSeq | GRCh38/hg38 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| PALB2 R37H | osteosarcoma | sensitive | Olaparib | Preclinical - Cell culture | Actionable | In a preclinical study, osteosarcoma cells expressing PALB2 R37H were sensitive to treatment with Lynparza (olaparib), demonstrating decreased cell growth in culture (PMID: 31586400). | 31586400 |
| PALB2 R37H | Advanced Solid Tumor | conflicting | Olaparib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing PALB2 R37H were sensitive to treatment with Lynparza (olaparib), demonstrating decreased cell growth in culture (PMID: 31586400). | 31586400 |
| PALB2 R37H | Advanced Solid Tumor | conflicting | Olaparib | Preclinical - Cell culture | Actionable | In a preclinical study, expressing PALB2 R37H did not confer sensitivity to Lynparza (olaparib)-induced growth inhibition in TP53 and PALB2 double knock-out mouse embryonic stem cells in culture (PMID: 33811135). | 33811135 |